Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib

Conclusions: RECIST 1.1 and WHO performed somewhat better than Choi criteria as TRC for response evaluation in patients with advanced GIST after prior failure on imatinib and sunitinib.

Source: European Journal of Cancer - January 6, 2014 Category: Cancer & Oncology Authors: Atul B. Shinagare, Jyothi P. Jagannathan, Vikram Kurra, Trinity Urban, Judith Manola, Edwin Choy, George D. Demetri, Suzanne George, Nikhil H. Ramaiya Tags: Sarcoma Source Type: research